Gary McCarthy’s Post

A rare example of SPAC success! Just goes to show, the SPAC structure is not necessarily evil, unless evil financial scammers get their sweaty paws on it and turn it all into a shell game.... "Bain Capital increased its commitment to the company about three years ago, participating in a $320 million private investment in public equity deal in conjunction with Cerevel’s transition to a public listing by combining with a special-purpose acquisition company backed by life-sciences investment firm Perceptive Advisors. At that point, Bain Capital held about 60 million shares valued at about $10.10 each, or roughly $606 million, and Cerevel’s equity value stood at $780 million, a securities filing shows." #SPAC #BIOTECH #PE #PRIVATEEQUITY #ABBVIE #PFIZER

Have you heard of Chromocell Therapeutics Corporation (NYSE American: CHRO)? 🤔 They just closed their initial public offering of 1,100,000 shares of their common stock at $6.00 per share, raising approximately $6.6 million. 💰 That’s a huge milestone for Chromocell Corporation. 🚀 They are a clinical-stage biotech company that is developing and commercializing new, non-opioid therapeutics to alleviate pain. 💊 This post is brought to you by Spiking Wealth Masterclass. Sign up for Early Bird at $0 now: https://spi.ke/mc25 They have a novel approach to target the sodium ion-channel known as NaV1.7, which is involved in various types of chronic neuropathic pain and eye pain. 👁️ They also have pre-clinical work on other sodium channel receptor subtypes and plan to explore them for the treatment of additional pain indications. 🔬 To get more updates on IPO, stock market, investment, and crypto currency, Follow Us! 😊 Also, don’t miss this chance to join the Spiking community and become a smart investor. 😎 Dr. Clemen Chiang (PhD, MBA) #CHRO #NYSE #IPO #Investing #Finance #FinancialEducation #FinancialSuccess #FinancialLiteracy #Trading #Spiking

The Venture Letter™ - Update Report on XORTX Therapeutics Inc.  (NASDAQ: XRTX / TSXV: XRTX / Frankfurt: ANUA) - I am pleased to provide interested investors with an update report on XORTX Therapeutics Inc. Since the beginning of 2024, there have been numerous multi-billion dollar, biotech buyouts that must be considered when considering becoming a shareholder in XORTX. Good luck and good hunting. #XORTX #TheVentureLetter #Biotechs #Buyouts #NASDAQ #TSXV #Biotechstocks #Stockmarkets #kidneydisease #orphandrugs

Afinum acquires a majority stake in evitria Abolon was mandated by Afinum Management GmbH, the DACH-based private equity firm, on its acquisition of a majority stake in Swiss biotech company evitria AG, which provides custom antibodies for research purposes. evitria has been conducting more than 30,000 transfections and has been producing more than 5,000 different antibodies to date. The company’s success is based on a unique, highly standardized and automatized production process that minimizes throughput times and guarantees high concentrations and quality levels, thereby perfectly addressing its customers’ need for specific, tailor-made antibodies. Its business model has allowed evitria to build a reputation of a superior biotech specialist and trustworthy outsourcing partner. The transaction has been closed in December 2018. The enterprise value was not made publicly available. Abolon Group was exclusively mandated by Afinum.

I take this as another positive indication of the upswing in Biotech investing! ...A trio of former investors from OrbiMed, ATP (Apple Tree Partners) and Medicxi has come together to form a new biotech fund called Scion Life Sciences. Scion has gathered $310 million, about $60 million over its initial target, to create six or seven new biotech companies, Aaron Kantoff, the VC fund’s co-founder and managing partner... “Our goal and mission is somewhere in here to create a truly special, durable operating company that has the ability to scale over time to look a lot like that of a Regeneron or Vertex Pharmaceuticals today,” Kantoff noted. He co-founded Scion alongside managing partners Sam Hall and Tadd Wessel.... #venturecapital #newfund #newmodel #operationalexcellence #opco #310m #biotech #biotechnology #lifesciences #cellandgenetherapy #advancedtherapies #investing #investment #geneticdisorders #biologics #companycreation #healthcareinnovation

What do you get when you combine our powerful Affinity Ligand Identification System (#ALIS) for Affinity Selection Mass Spectroscopy (#ASMS) with Axxam's AXXDiversity library of ~349K curated small molecules? Unprecedented capacity to support client innovation through high-throughput screening for drug discovery! Check out the full webinar linked below for more information about the research possibilities enabled by this exciting collaboration.    #DrugDiscovery #HighThroughputScreening #AffinitySelectionMassSpectroscopy 

🎉Congratulations from Checkmate Equity🎉 💼Company: Attovia Therapeutics💰#Funding: $105Million⚡Round: Series B 👥Investors: Goldman Sachs Alternatives, Cormorant Asset Management, LP, Nextech Ventures, Redmile Group, EcoR1 Capital, LLC, Marshall Wace, and Logos Capital. Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages ATTOBODY™, a biparatopic biologics platform, to generate binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. 🚀OFFLOAD YOUR CAP TABLE MANAGEMENT TASKS TODAY🎉 Checkmate Equity is a trusted Carta partner with experience managing over 2,000 #captables. Our expertise ensures compliance, accuracy, and timely updates for your cap table. With a dedicated Equity Administrator, we streamline the process, ensuring rapid updates. 🚀 Tao Fu and Zaneta Odrowaz, let me know if you need assistance with the adjustments to your Cap Table. 📊

The Venture Letter™ - Update Report on XORTX Therapeutics Inc. (NASDAQ: XRTX / TSXV: XRTX / Frankfurt: ANUA) - We are pleased to provide interested investors with an update report on XORTX Therapeutics Inc. Since the beginning of 2024, there have been numerous multi-billion dollar, biotech buyouts that must be considered when considering becoming a shareholder in XORTX. Good luck and good hunting. #XORTX #TheVentureLetter #Biotechs #Buyouts #NASDAQ #TSXV #Biotechstocks

𝐀𝐫𝐞 𝐲𝐨𝐮 𝐚 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐕𝐂 𝐟𝐮𝐧𝐝 𝐨𝐫 𝐟𝐚𝐦𝐢𝐥𝐲 𝐨𝐟𝐟𝐢𝐜𝐞? 📚 We support VC funds and family offices by bolstering their technical due diligence and closing funding rounds by mitigating investor risk in new drug technologies and therapeutics. Visit our website in the comments below. #biotechnolgy #venturecapital #vcfund #proteinprediction #admet

💲🤑☀ A warm and humid week here in the UK, and I know a lot of people are struggling (as we always do in the heat). The good news is the investment market isn't cooling down either, so have a look at my video below for the overview. 🤖 Formation Bio - $372 million series D 🧬 BillionToOne - $130 million series D 💰 Endogenex - $88 million series C 💊 Exsilio Therapeutics - $82 million 💸 VICO Therapeutics B.V. - $70 million series B #financialfridays #biotechinvestment #venturecapitalist #vcinvestment